Techno Trends
TechnoTrends provide comprehensive coverage of the innovations and inventions in pharma products and pharma technologies across the world. The up-to-date listing of latest pharmaceutical product news and technology trends in the global pharma industry, keeps you abreast with all the latest pharmaceutical innovations happening world over.
Johnson & Johnson Introduced First and Only RYBREVANT® for Non-Small Lung Cancer
Johnson & Johnson has announced the Health Canada approval of RYBREVANT® (amivantamab for injection) in combination with carboplatin and pemetrexed for treating locally advanced or metastatic non-small cell lung cancer (NSCLC)....
Genentech Unveils First and Only Susvimo® for the Treatment of Diabetic Macular Oedema
Genentech has introduced Susvimo® (ranibizumab injection) 100 mg/mL as the first continuous drug delivery system for adults with diabetic macular oedema (DME), a leading cause of vision loss in people with diabetes...
Alnylam Introduced First and Only AMVUTTRA® (vutrisiran) for ATTR Amyloidosis with Cardiomyopathy (ATTR-CM)
Alnylam Pharmaceuticals has AMVUTTRA® (vutrisiran) as the first and only FDA-approved treatment for adults with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM) to reduce cardiovascular mortality, hospitalisations, and urgent heart failure visits...
Johnson & Johnson Unveils First and Only TREMFYA® (guselkumab) for the Treatment of Crohn’s Disease
Johnson & Johnson has introduced TREMFYA® (guselkumab) as the first and only FDA-approved IL-23 inhibitor offering both subcutaneous (SC) and intravenous (IV) induction options for adults with moderately to severely active Crohn’s disease (CD)....
Genentech Unveils First and Only TNKase® for Acute Ischaemic Stroke Management
Genentech has unveiled TNKase® (tenecteplase) as a new treatment option for acute ischaemic stroke (AIS) in adults, making it the first and only single-bolus thrombolytic therapy approved for AIS in the United States. TNKase is a thrombolytic agent designed to dissolve blood clots. It is administered...
Fapon Biopharma Launches First-in-Class FP008 Immunotherapy for Solid Tumours
Fapon Biopharma has introduced FP008 as a pioneering immunotherapy designed for patients with solid tumours that are resistant to anti-PD-1 treatment, addressing a critical unmet medical need in oncology. FP008 is a novel anti-PD-1×IL-10M fusion protein designed to enhance immune response...
GRIN Therapeutics Introduces Breakthrough Radiprodil in GRIN-Related Neurodevelopmental Disorder
GRIN Therapeutics has introduced radiprodil, an investigational treatment for seizures associated with GRIN-related neurodevelopmental disorder caused by gain-of-function (GoF) mutations. Radiprodil is designed to selectively modulate GluN2B, a receptor subtype linked to neurodevelopmental disorders...
Neurotech Pharmaceuticals Unveils First and Only ENCELTO™ for Macular Telangiectasia Type 2
Neurotech Pharmaceuticals has introduced ENCELTO™ (revakinagene taroretcel-lwey) as the first and only FDA-approved treatment for adults with Macular Telangiectasia Type 2 (MacTel), a progressive neurodegenerative eye disease that leads to irreversible vision loss....
GSK Discovers GSK’227 for Relapsed or Refractory Osteosarcoma
GSK has developed GSK’227 (GSK5764227) for the treatment of adult patients with relapsed or refractory osteosarcoma who have progressed after at least two prior lines of therapy....
Rezolute Unveils Breakthrough Ersodetug for Hypoglycemia Patients
Rezolute unveils breakthrough ersodetug (RZ358) for patients with hypoglycemia caused by congenital hyperinsulinism (HI), a rare and life-threatening condition....
